Pay in 4 interest-free payments of $6.06 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
This matters most in groups already vulnerable to changes in bone density, including: Post-menopausal women Adults over 50 Individuals with low resistance training exposure Athletes experiencing chronically low energy availability GLP-1 therapy is not contraindicated for these groups
It suppresses pro-inflammatory cytokines (e.g., IL-1, TNF-) and NF-B signaling, reducing inflammation linked to aging and injury
No guesswork herejust real results
Type 2 Diabetes Research Glycemic Control Studies Phase 2 investigations in adults with type 2 diabetes demonstrated dual benefits on both glucose control and body weight[13]: HbA1c reductions of 1.39% to 2.02% with GLP3 at 4 mg to 12 mg at 24 weeks Body weight reductions of 7.92% to 16.94% at 36 weeks depending on dose 72% of participants with prediabetes at baseline reverted to normoglycemia with GLP3 treatment Improvements in fasting glucose, insulin levels, and measures of insulin sensitivity Effects exceeded those observed with dulaglutide (a GLP-1 receptor agonist) comparator Beta Cell Function and Insulin Sensitivity Mechanistic studies in participants with type 2 diabetes revealed: Enhanced markers of pancreatic beta cell function Improved insulin sensitivity indices Sustained glycemic control throughout 36-week treatment period Glucose-lowering effects observed even in participants with relatively preserved beta cell function Cardiometabolic Effects Research Lipid Profile Improvements Clinical trials documented significant improvements in cardiovascular risk markers[14]: Low-density lipoprotein cholesterol reductions of approximately 20% Triglyceride reductions of up to 50% with higher doses VLDL cholesterol decreases paralleling triglyceride improvements Minimal changes in HDL cholesterol levels Potential mechanisms include glucagon receptor-mediated effects on PCSK9 degradation Blood Pressure and Cardiac Parameters Cardiovascular monitoring in phase 2 trials revealed: Systolic blood pressure reductions of 5 to 10 mmHg depending on dose Diastolic blood pressure improvements of 3 to 5 mmHg Dose-dependent increases in heart rate (peak at 24 weeks, declining thereafter) Heart rate changes similar to those observed with other GLP-1 or GLP-1/GIP receptor agonists Body Composition Research A dedicated substudy examined the quality of weight loss using dual-energy X-ray absorptiometry (DEXA) scans[15]: Total body fat mass reductions significantly greater than placebo and dulaglutide comparator Proportion of lean mass loss to total weight loss similar to other obesity treatments (approximately 25-30%) Preferential reduction in visceral adipose tissue compared to subcutaneous fat Preservation of lean mass relative to overall weight loss comparable to surgical weight loss interventions [CALLOUT BOX Highlighted] Critical Limitation: All published efficacy data derive from clinical trials lasting 48 weeks or less
